flecainide has been researched along with transforming growth factor beta in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baró, I; Cerpa, CO; Charpentier, F; Colledge, WH; Derangeon, M; Girardeau, A; Grace, AA; Huang, CLH; Jagu, B; Montnach, J; Patin, J; Toumaniantz, G | 1 |
1 other study(ies) available for flecainide and transforming growth factor beta
| Article | Year |
|---|---|
Transforming growth factor β receptor inhibition prevents ventricular fibrosis in a mouse model of progressive cardiac conduction disease.
Topics: Age Factors; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzamides; Cardiomyopathies; Connexin 43; Disease Models, Animal; Female; Fibrosis; Flecainide; Genetic Predisposition to Disease; Heart Conduction System; Heart Rate; Heart Ventricles; Heterozygote; Kinetics; Male; Membrane Potentials; Mice, 129 Strain; Mice, Knockout; NAV1.5 Voltage-Gated Sodium Channel; Phenotype; Pyrazoles; Receptors, Transforming Growth Factor beta; Signal Transduction; Transforming Growth Factor beta; Ventricular Remodeling; Voltage-Gated Sodium Channel Blockers | 2017 |